Fig. 3
From: Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
Persistent mTOR signaling in response to IGF-1R inhibition is overcome by MK-8669. Western Blot analysis of MCF-7/AC-1 (a) and MCF-7/AC-1/IGF-2 (b) cells treated with one or more of the following agents for 24 h at the indicated dose(s): LET (1uM), MK-0646 (1.25, 2.5, 5 ng/uL) and/or MK-8669 (100, 500, 1000 nM). IGF-1 was added for 10 min prior to harvest for the indicated samples